相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A phase 2 dose-finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis
Cihan Yurdaydin et al.
HEPATOLOGY (2022)
Getting to HBV cure: The promising paths forward
Scott Fung et al.
HEPATOLOGY (2022)
Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis
Alessandro Loglio et al.
JOURNAL OF HEPATOLOGY (2022)
Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment
Man-Fung Yuen et al.
GUT (2022)
Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide-Results of A real world Study
Mathias Jachs et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2022)
Hepatitis delta treatment with bulevirtide in real life: a case report
Marc-Antoine Giordan et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2022)
Efficacy and Safety of Bulevirtide plus Tenofovir Disoproxil Fumarate in Real-World Patients with Chronic Hepatitis B and D Co-Infection
Toni Herta et al.
PATHOGENS (2022)
Antiviral Activity and Pharmacokinetics of the Hepatitis B Virus (HBV) Capsid Assembly Modulator GLS4 in Patients With Chronic HBV Infection
Hong Zhang et al.
CLINICAL INFECTIOUS DISEASES (2021)
Effectiveness of pegylated interferon monotherapy in the treatment of chronic hepatitis D virus infection: A meta-analysis
Aigerim Abdrakhman et al.
ANTIVIRAL RESEARCH (2021)
The changing context of hepatitis D
Mario Rizzetto et al.
JOURNAL OF HEPATOLOGY (2021)
Residual low HDV viraemia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: Results from the HIDIT-II study
Birgit Bremer et al.
LIVER INTERNATIONAL (2021)
The FDA approves a first farnesyltransferase inhibitor
Asher Mullard
NATURE REVIEWS DRUG DISCOVERY (2021)
HBsAg, Subviral Particles, and Their Clearance in Establishing a Functional Cure of Chronic Hepatitis B Virus Infection
Andrew Vaillant
ACS INFECTIOUS DISEASES (2021)
Safety, Pharmacokinetics, and Pharmacodynamics of the Oral TLR8 Agonist Selgantolimod in Chronic Hepatitis B
Edward J. Gane et al.
HEPATOLOGY (2021)
Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial
Man-Fung Yuen et al.
NATURE MEDICINE (2021)
Clinical and Preclinical Single-Dose Pharmacokinetics of VIR-2218, an RNAi Therapeutic Targeting HBV Infection
Sneha Gupta et al.
DRUGS IN R&D (2021)
Protein N-myristoylation: functions and mechanisms in control of innate immunity
Bin Wang et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2021)
Early virological response in six patients with hepatitis D virus infection and compensated cirrhosis treated with Bulevirtide in real-life
Tarik Asselah et al.
LIVER INTERNATIONAL (2021)
Safety, Tolerability, and Pharmacokinetics of the Novel Hepatitis B Virus Capsid Assembly Modulator GST-HG141 in Healthy Chinese Subjects: a First-in-Human Single- and Multiple-Dose Escalation Trial
Cuiyun Li et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease
Stephan Urban et al.
GUT (2021)
Persistent Control of Hepatitis B Virus and Hepatitis Delta Virus Infection Following REP 2139-Ca and Pegylated Interferon Therapy in Chronic Hepatitis B Virus/Hepatitis Delta Virus Coinfection
Michel Bazinet et al.
HEPATOLOGY COMMUNICATIONS (2021)
A First-in-Human Trial of GLS4, a Novel Inhibitor of Hepatitis B Virus Capsid Assembly, following Single- and Multiple-Ascending-Oral-Dose Studies with or without Ritonavir in Healthy Adult Volunteers
Nan Zhao et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
RNA Interference Therapy With ARC-520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection
Man-Fung Yuen et al.
HEPATOLOGY (2020)
Estimating the Global Prevalence, Disease Progression, and Clinical Outcome of Hepatitis Delta Virus Infection
Zhijiang Miao et al.
JOURNAL OF INFECTIOUS DISEASES (2020)
Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naive to Nucleos(t)ide Therapy
Michel Bazinet et al.
GASTROENTEROLOGY (2020)
JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection
Fabien Zoulim et al.
GASTROENTEROLOGY (2020)
Hepatitis B surface antigen seroclearance: Immune mechanisms, clinical impact, importance for drug development
Issam Tout et al.
JOURNAL OF HEPATOLOGY (2020)
The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis
Alexander J. Stockdale et al.
JOURNAL OF HEPATOLOGY (2020)
The efficacy of hepatitis B treatments in achieving HBsAg seroclearance: A systematic review and meta-analysis
Mariana Alves Fonseca et al.
JOURNAL OF VIRAL HEPATITIS (2020)
Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta
Dominique Roulot et al.
JOURNAL OF HEPATOLOGY (2020)
A Five-in-One First-in-Human Study To Assess Safety, Tolerability, and Pharmacokinetics of RO7049389, an Inhibitor of Hepatitis B Virus Capsid Assembly, after Single and Multiple Ascending Doses in Healthy Participants
Sheng Feng et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Virology analysis of chronic hepatitis B virus-infected patients treated for 28 days with JNJ-56136379 monotherapy
Thierry Verbinnen et al.
JOURNAL OF VIRAL HEPATITIS (2020)
Revisiting the estimation of hepatitis D global prevalence
Zhijiang Miao et al.
JOURNAL OF HEPATOLOGY (2020)
Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis
Hai-Yan Chen et al.
GUT (2019)
Antiviral treatment with pegylated interferon and clinical outcomes in a cohort of immigrants patients affected by hepatitis delta: A retrospective analysis
Lucio Boglione et al.
JOURNAL OF MEDICAL VIROLOGY (2019)
Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial
Heiner Wedemeyer et al.
LANCET INFECTIOUS DISEASES (2019)
Pharmacokinetics, Safety and Tolerability of JNJ-56136379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy Subjects
Joris Vandenbossche et al.
ADVANCES IN THERAPY (2019)
Excellent safety and effectiveness of high-dose myrcludex-B monotherapy administered for 48 weeks in HDV-related compensated cirrhosis: A case report of 3 patients
Alessandro Loglio et al.
JOURNAL OF HEPATOLOGY (2019)
Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study
Edward Gane et al.
JOURNAL OF HEPATOLOGY (2019)
Therapeutic strategies for hepatitis B virus infection: towards a cure
Gregory C. Fanning et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
REP 2139: Antiviral Mechanisms and Applications in Achieving Functional Control of HBV and HDV Infection
Andrew Vaillant
ACS INFECTIOUS DISEASES (2019)
Pathogenesis of and New Therapies for Hepatitis D
Christopher Koh et al.
GASTROENTEROLOGY (2019)
Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection
Man Fung Yuen et al.
GASTROENTEROLOGY (2019)
Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy
Cihan Yurdaydin et al.
JOURNAL OF HEPATOLOGY (2019)
Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study
Cihan Yurdaydin et al.
HEPATOLOGY (2018)
Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B
Harry L. A. Janssen et al.
JOURNAL OF HEPATOLOGY (2018)
Safety and efficacy of vesatolimod (GS-9620) in patients with chronic hepatitis B who are not currently on antiviral treatment
K. Agarwal et al.
JOURNAL OF VIRAL HEPATITIS (2018)
Hepatitis D diagnostics:Utilization and testing in the United States
Parham Safaie et al.
VIRUS RESEARCH (2018)
GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics
Aaron D. Springer et al.
NUCLEIC ACID THERAPEUTICS (2018)
A phase 2 study exploring once daily dosing of ritonavir boosted lonafarnib for the treatment of chronic delta hepatitis - end of study results from the LOWR HDV-3 study
C. Koh et al.
JOURNAL OF HEPATOLOGY (2017)
RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg
Christine I. Wooddell et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial
Michel Bazinet et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2017)
A targeted functional RNA interference screen uncovers glypican 5 as an entry factor for hepatitis B and D viruses
Eloi R. Verrier et al.
HEPATOLOGY (2016)
Nucleic acid polymers: Broad spectrum antiviral activity, antiviral mechanisms and optimization for the treatment of hepatitis B and hepatitis D infection
Andrew Vaillant
ANTIVIRAL RESEARCH (2016)
Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B)
Henry L. Y. Chan et al.
JOURNAL OF HEPATOLOGY (2016)
Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study
Pavel Bogomolov et al.
JOURNAL OF HEPATOLOGY (2016)
Co-treatment with pegylated interferon alfa-2a and entecavir for hepatitis D: A randomized trial
Zaigham Abbas et al.
WORLD JOURNAL OF HEPATOLOGY (2016)
Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome
Onur Keskin et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
Pegylated Interferon α Therapy in Chronic Delta Hepatitis: A One-Center Experience
Ibrahim Halil Bahcecioglu et al.
HEPATITIS MONTHLY (2015)
The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection
Edward J. Gane et al.
JOURNAL OF HEPATOLOGY (2015)
Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B
Stephan Menne et al.
JOURNAL OF HEPATOLOGY (2015)
Long-term therapy of chronic delta hepatitis with peginterferon alfa
T. Heller et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
Treatment of chronic hepatitis D patients with pegylated interferon: a real-world experience
Zaigham Abbas et al.
ANTIVIRAL THERAPY (2014)
Strategies to Inhibit Entry of HBV and HDV Into Hepatocytes
Stephan Urban et al.
GASTROENTEROLOGY (2014)
Late HDV RNA Relapse After Peginterferon Alpha-Based Therapy of Chronic Hepatitis Delta
Benjamin Heidrich et al.
HEPATOLOGY (2014)
A one step real time PCR method for the quantification of hepatitis delta virus RNA using an external armored RNA standard and intrinsic internal control
Ersin Karatayli et al.
JOURNAL OF CLINICAL VIROLOGY (2014)
Efficacy of pegylated interferon-α treatment for 24 months in chronic delta hepatitis and predictors of response
Cetin Karaca et al.
ANTIVIRAL THERAPY (2013)
The Third Signal Cytokine IL-12 Rescues the Anti-Viral Function of Exhausted HBV-Specific CD8 T Cells
Anna Schurich et al.
PLOS PATHOGENS (2013)
Silencing disease genes in the laboratory and the clinic
Jonathan K. Watts et al.
JOURNAL OF PATHOLOGY (2012)
Treatment of Chronic Delta Hepatitis: A Nine-Year Retrospective Analysis
Serda Gulsun et al.
HEPATITIS MONTHLY (2011)
Peginterferon plus Adefovir versus Either Drug Alone for Hepatitis Delta
Heiner Wedemeyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Interaction of Host Cellular Proteins with Components of the Hepatitis Delta Virus
Valerie Greco-Stewart et al.
VIRUSES-BASEL (2010)
The hepatitis delta virus RNA genome interacts with the human RNA polymerases I and III
Valerie S. Greco-Stewart et al.
VIROLOGY (2009)
Treatment of chronic delta hepatitis with lamivudine vs lamivudine plus interferon vs interferon
C. Yurdaydin et al.
JOURNAL OF VIRAL HEPATITIS (2008)
Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy:: A randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine
Pierre Vandepapeliere et al.
VACCINE (2007)
Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans
Andreas Schulze et al.
HEPATOLOGY (2007)
Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection
Carolina Boni et al.
JOURNAL OF VIROLOGY (2007)
Efficacy of peginterferon alpha-2b in chronic hepatitis delta:: Relevance of quantitative RT-PCR for follow-up
Corinne Castelnau et al.
HEPATOLOGY (2006)
Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta
Grazia Anna Niro et al.
HEPATOLOGY (2006)
Treatment of chronic hepatitis delta with pegylated interferon-α2b
Andreas Erhardt et al.
LIVER INTERNATIONAL (2006)
Roles of carboxyl-terminal and farnesylated residues in the functions of the large hepatitis delta antigen
B O'Malley et al.
JOURNAL OF VIROLOGY (2005)
Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers
M Mancini-Bourgine et al.
HEPATOLOGY (2004)
Prenylation inhibitors: a novel class of antiviral agents
S Einav et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2003)
Replicating hepatitis delta virus RNA is edited in the nucleus by the small form of ADAR1
SK Wong et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
A prenylation inhibitor prevents production of infectious hepatitis delta virus particles
BB Bordier et al.
JOURNAL OF VIROLOGY (2002)
A novel chromosome region maintenance 1-independent nuclear export signal of the large form of hepatitis delta antigen that is required for the viral assembly
CH Lee et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
The large delta antigen of hepatitis delta virus potently inhibits genomic but not antigenomic RNA synthesis: a mechanism enabling initiation of viral replication
LE Modahl et al.
JOURNAL OF VIROLOGY (2000)
RNA-dependent replication and transcription of hepatitis delta virus RNA involve distinct cellular RNA polymerases
LE Modahl et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
分享论文
